1. Home
  2. XAIR vs DRMA Comparison

XAIR vs DRMA Comparison

Compare XAIR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.38

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
DRMA
Founded
2011
2014
Country
United States
United States
Employees
N/A
9
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.1M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
XAIR
DRMA
Price
$0.38
$1.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$10.00
$10.00
AVG Volume (30 Days)
228.3K
48.3K
Earning Date
06-16-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
62.09
N/A
EPS
N/A
N/A
Revenue
$3,705,000.00
N/A
Revenue This Year
$122.00
N/A
Revenue Next Year
$58.15
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
219.67
N/A
52 Week Low
$0.15
$0.59
52 Week High
$3.78
$7.33

Technical Indicators

Market Signals
Indicator
XAIR
DRMA
Relative Strength Index (RSI) 33.65 45.12
Support Level N/A $1.13
Resistance Level $0.59 $1.40
Average True Range (ATR) 0.05 0.08
MACD -0.00 -0.01
Stochastic Oscillator 3.71 13.64

Price Performance

Historical Comparison
XAIR
DRMA

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: